Adebrelimab

Org: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China, Department of Oncology, XiangYang Central Hospital, Hubei University of Arts and Science, Xiangyang, China, Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China,

Abstract

Open-label, phase 2 study of adebrelimab combined with fuzuloparib in the treatment of patients with HRD-positive, recurrent platinum-resistant ovarian cancer.

Org: Clinical Oncology School of Fujian Medical University,

Abstract

Neoadjuvant adebrelimab plus dalpiciclib in HPV-negative locally advanced head and neck squamous cell carcinoma: A phase II clinical trial.

Org: National Clinical Research Center for Oral Diseases, Department of Head and Neck Oncology Surgery,

Abstract

A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.

Org: First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology Co. Ltd,

Abstract

Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study.

Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Union Hospital Medical College,

Clinical trial

Phase II Clinical Study of Adebrelimab Combined With Apatinib and Tegafur in the Treatment of Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma That Failed First-line Immunotherapy Combined With Chemotherapy

Status: Recruiting, Estimated PCD: 2026-03-01

Abstract

Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.

Org: Affiliated Hospital of Shandong First Medical University,

Clinical trial

Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Status: Not yet recruiting, Estimated PCD: 2026-05-31

Clinical trial

A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2026-06-30

Clinical trial

A Single Arm, Exploratory Clinical Study of the Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma in Clinical Practice

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic Chemotherapy of Vinorelbine, Cyclophosphamide and Capecitabine (VEX) Regime in Advanced Triple-negative Breast Cancer: a Multicenter, Randomized, Phase II Study

Status: Not yet recruiting, Estimated PCD: 2025-01-19

Clinical trial

An Open-label, Multi-center Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2025-12-01

Clinical trial

Adebrelimab Combined With Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma: a Phase 2, Multicenter, Single-arm Clinical Trial

Status: Not yet recruiting, Estimated PCD: 2028-05-01

Clinical trial

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer:a Single-arm, Phase II Exploratory Clinical Study

Status: Recruiting, Estimated PCD: 2025-11-30

Clinical trial

Disitamab Vedotin Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer With HER2 Overexpression: a Prospective, Phase II Study

Status: Not yet recruiting, Estimated PCD: 2027-05-01

Clinical trial

An Exploratory Clinical Trial of SHR-8068 Combined With Aldebelizumab and BP102 in the Treatment of Refractory Colorectal Cancer

Status: Not yet recruiting, Estimated PCD: 2026-11-01

Clinical trial

Hepatic Arterial Infusion Chemotherapy Combined With Adebrelimab and Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer: a Single-arm, Exploratory Clinical Study

Status: Not yet recruiting, Estimated PCD: 2027-05-01

Clinical trial

A Phase IB/II Clinical Study on the Safety, Tolerability and Efficacy of HRS-4642 in Combination With Anti-tumor Medication in Subjects With Advanced Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2025-10-01

Clinical trial

Efficacy and Safety of Stereotactic Body Radiotherapy Followed by Adebrelimab and Lenvatinib for Hepatocellular Carcinoma With Abdominal Lymph Node Metastases: A Two-arm, Phase II Trial

Status: Recruiting, Estimated PCD: 2026-06-30

Clinical trial

A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2027-07-01

Clinical trial

A Prospective, Single-arm, Multicenter Phase II Clinical Study of Hepatic Arterial Perfusion Chemotherapy (FOLFOX) in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma

Status: Not yet recruiting, Estimated PCD: 2025-05-01

Clinical trial

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors：NEO-ERA-01 Study

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Status: Not yet recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Status: Not yet recruiting, Estimated PCD: 2025-08-31

Clinical trial

A Multi-center, Open Label Study of Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Status: Recruiting, Estimated PCD: 2023-12-10

Clinical trial

A Single-arm Prospective Clinical Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin for the Neoadjuvant Treatment of Biliary Tract Malignancies

Status: Recruiting, Estimated PCD: 2029-02-23

Clinical trial

A Phase II, Single-arm, Two-cohorts, Open-label, Single Center Study of Surufatinib or Surufatinib Combined With Vinorelbine as Third-line and Posterior Line Treatment in Patients With Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer: a Prospective, Multicenter, Single-arm Study

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage

Status: Not yet recruiting, Estimated PCD: 2025-02-25

Clinical trial

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma: A Prospective, Single-arm Study

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Single Arm, Exploratory Clinical Study on the Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Status: Recruiting, Estimated PCD: 2027-03-01

Clinical trial

A Randomized, Controlled, Multicenter Phase II Clinical Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Status: Recruiting, Estimated PCD: 2027-05-19

Product

Adebrelimab + Fuzuloparib

Clinical trial

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma

Status: Not yet recruiting, Estimated PCD: 2026-06-17

Clinical trial

Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer: A Randomized, Open-label, Multicenter, Phase II Study

Status: Not yet recruiting, Estimated PCD: 2026-12-30

Clinical trial

A Phase 2 Study of SHR-A1921 Combined Adebrelimab in Endocrine Therapy-failed HR-positive, HER2-negative Advanced Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2026-03-01

Clinical trial

A Phase II Trial of Adebrelimab in Combination With NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma: a Single-arm, Multicenter, Phase II Clinical Study

Status: Not yet recruiting, Estimated PCD: 2026-07-13

Clinical trial

A Single-arm, Prospective, Exploratory Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2026-07-01